New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
13:48 EDTMLNX, NIHD, NPSPOptions with decreasing option implied volatility; MLNX NIHD NUS NPSP
News For MLNX;NIHD;NPSP From The Last 14 Days
Check below for free stories on MLNX;NIHD;NPSP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 12, 2014
07:47 EDTNPSPNPS Pharmaceuticals to host conference call
Subscribe for More Information
07:17 EDTNPSPFDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
The Committee discusses NPSP Pharmaceuticals' Biologics License Application (BLA) 125511, proposed trade name, NATPARA, (established name: Recombinant Human Parathyroid Hormone (rDNA) or (rhPTH), for the proposed indication of replacement for parathyroid hormone (1-84) for the long-term treatment of hypoparathyroidism will be held in Hyattsville, Maryland on September 12 at 8 am. Webcast Link
07:09 EDTNPSPNPS Pharma stock trading halted, FDA to review Natpara BLA
Subscribe for More Information
07:00 EDTNPSPNPS Pharmaceuticals trading halted, pending news
Subscribe for More Information
September 11, 2014
11:07 EDTNPSPOptions with decreasing implied volatility
Subscribe for More Information
06:02 EDTNPSPNPS could trade to high $30s on positive vote, says Leerink
Leerink believes an FDA advisory committee tomorrow will vote in favor of NPS Pharmaceuticals' Natpara as a chronic treatment for hypoparathyroidism. It says shares could trade in the mid-to-high $30s on a positive vote with further upside on FDA approval by October 24. The firm reiterates an Outperform rating on NPS Pharmaceuticals with a $40 price target.
September 10, 2014
16:19 EDTNPSPOn The Fly: Closing Wrap
Subscribe for More Information
13:03 EDTNPSPOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday, with the Nasdaq comfortably the leader among the major averages. The market opened relatively quietly as investors digested the bevy of research reports surrounding apple (AAPL) and the companies effected by its new products and services announced yesterday. The averages crossed into negative ground early in trading, made it back to positive territory just before the lunch hour, and now are all in the black. ECONOMIC EVENTS: In the U.S., wholesale inventories rose 0.1% in July, which was below expectations for an increase of 0.5%. Wholesale sales rose 0.7%, which was above the 0.6% increase that was forecast. COMPANY NEWS: The strength in the Nasdaq was largely attributable to Apple, which rose about 2.5% the day after unveiling two new, larger iPhone 6 models, the Apple Watch and a new payment system, named Apple Pay... Dollar General (DG) "went hostile" in its pursuit of peer Family Dollar (FDO), commencing a tender offer to acquire all of the company's outstanding shares for $80.00 per share in cash. Family Dollar confirmed the unsolicited offer, noting that the terms are the same as those in the previously rejected proposal made by Dollar General on September 2. Family Dollar said its board will review and consider Dollar Generalís tender offer, but added that the board has not changed its recommendation in support of the company's merger with Dollar Tree (DLTR). MAJOR MOVERS: Among the notable gainers was NPS Pharmaceuticals (NPSP), which rose 21% after several analysts said FDA briefing documents for an advisory panel meeting on its Natpara drug were more favorable than expected. Also higher was clothing and accessories retailer Land's End (LE), which gained nearly 17% after the company's second quarter results beat the estimate of the only analyst that covers it. Among the noteworthy losers was eBay (EBAY), which fell for a second straight day after Apple announced its new mobile payment system, Apple Pay, that could come in direct competition with eBay's PayPal service. Shares of PayPal's parent were downgraded to Neutral this morning at Piper Jaffray and fell 3% near noon. Also lower following yesterday's presentation by Apple was partner GT Advanced (GTAT), which was downgraded at Goldman, Piper Jaffray and Dougherty and dropped more than 14% after it was revealed that sapphire will be used in the display cover of Apple Watch but not the iPhone 6. INDEXES: Near midday, the Dow was up 16.02, or 0.09%, to 17,029.89, the Nasdaq was up 21.10, or 0.46%, to 4,573.38, and the S&P 500 was up 2.62, or 0.13%, to 1,991.06.
11:48 EDTNPSPStocks with call strike movement; GTAT NPSP
GT Advanced (GTAT) March 15 call option implied volatility decreased 6% to 39, NPS Pharmaceuticals (NPSP) January 35 call option implied volatility decreased 17% to 60 according to IVolatility.
11:11 EDTNPSPNPS Pharmaceuticals management to meet with Needham
Meetings to be held in Chicago on September 16 and in Kansas City/Minneapolis on September 17 hosted by Needham.
10:51 EDTNPSPNPS briefing docs more favorable than expected, says FBR Capital
Subscribe for More Information
10:48 EDTNPSPNPS briefing docs 'much less negative' than feared, says Leerink
Subscribe for More Information
10:36 EDTNPSPNPS Pharmaceuticals briefing docs for Naptara benign, says Canaccord
Subscribe for More Information
08:27 EDTNPSPNPS Pharmaceuticals rises after FDA briefing materials posted
Subscribe for More Information
08:06 EDTNPSPNPS says FDA posts briefing materials for meeting reviewing Natpara
Subscribe for More Information
September 9, 2014
15:13 EDTNPSPNPS Pharmaceuticals September volatility elevated into PDUFA
Subscribe for More Information
09:22 EDTMLNXMellanox storage opportunity underappreciated, says Summit Research
Subscribe for More Information
08:17 EDTNPSPNPS Pharmaceuticals likely volatile on briefing docs, says FBR Capital
Subscribe for More Information
September 8, 2014
14:37 EDTNPSPNPS Pharmaceuticals September volatility elevated into PDUFA
Subscribe for More Information
11:05 EDTNPSPOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use